StockWatch
·
Biotechnology: Electromedical & Electrotherapeutic Apparatus
DelistingJul 27, 2026, 05:31 PM

Nexalin Technology Faces Nasdaq Delisting; Company Appeals

AI Summary

Nexalin Technology, Inc. received a Delisting Notice from Nasdaq on July 24, 2026, for failing to comply with the minimum bid price requirement and the $5,000,000 minimum stockholders' equity rule. The company's securities are scheduled for delisting and suspension from The Nasdaq Capital Market at the opening of business on August 4, 2026. Nexalin Technology has requested a hearing to appeal Nasdaq's determination, which will stay the suspension pending the Panel's decision.

Key Highlights

  • Nasdaq notified Nexalin Technology on January 21, 2026, of non-compliance with the $1.00 minimum bid price rule.
  • The company had until July 20, 2026, to regain compliance with the minimum bid price requirement.
  • On July 24, 2026, Nasdaq issued a Delisting Notice due to continued non-compliance.
  • The company also failed to meet the $5,000,000 minimum stockholders' equity requirement.
  • Nasdaq scheduled the company's securities for delisting and suspension on August 4, 2026.
  • Nexalin Technology has timely requested a hearing before a Nasdaq Hearings Panel to appeal the determination.